文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

TAVR术后早期左室射血分数改善与5年临床结局的关联

Association Between Early Left Ventricular Ejection Fraction Improvement After Transcatheter Aortic Valve Replacement and 5-Year Clinical Outcomes.
PubMed 文献 · JAMA Cardiol · 2022-01-01

该队列研究纳入PARTNER 1、2和S3试验及注册研究中659例基线LVEF<50%的经股动脉TAVR患者,32.8%在30天内LVEF改善≥10个百分点。早期LVEF改善与较低的5年全因死亡和心源性死亡相关,连续变量分析显示LVEF每增加5%,5年全因死亡风险比为0.94。

要点

  • 约1/3的LVEF<50%患者在TAVR术后1个月内出现LVEF改善≥10个百分点
  • 早期LVEF改善与5年全因死亡和心源性死亡降低独立相关
  • LVEF改善与5年再住院、NYHA心功能分级或KCCQ评分无显著差异

核心结论

  • 在重度主动脉瓣狭窄且LVEF<50%的患者中,TAVR术后早期LVEF改善与较低的5年全因死亡和心源性死亡相关。

研究设计与样本

  • 该队列研究分析PARTNER 1、2和S3试验及注册研究中2007年7月至2015年4月入组的患者。
  • 纳入659例基线LVEF<50%并接受经股动脉TAVR的高危或中危患者。
  • 早期LVEF改善定义为30天时LVEF增加≥10个百分点,同时也作为连续变量(基线与30天之间的ΔLVEF)分析。

主要发现

  • 216例(32.8%)在TAVR术后30天内出现LVEF改善,平均ΔLVEF为16.4%(SD 5.7%)。
  • 限制性立方样条分析显示ΔLVEF在10%处存在视觉拐点,超过该点后全因死亡率随LVEF改善程度增加而陡降。

关键数值与推荐

  • 早期LVEF改善定义为TAVR术后30天时LVEF增加≥10个百分点。
  • LVEF每增加5%,5年全因死亡风险比为0.94(95% CI 0.88-1.00),心源性死亡风险比为0.90(95% CI 0.82-0.98)。
  • 有早期LVEF改善者5年全因死亡率为50.0%(95% CI 43.3-57.1),无改善者为58.4%(95% CI 53.6-63.2)。
  • 有早期LVEF改善者5年心源性死亡率为29.5%(95% CI 23.2-37.1),无改善者为38.1%(95% CI 33.1-43.6)。

临床怎么用

  • 对于LVEF<50%的重度主动脉瓣狭窄患者,TAVR术后30天内应复查LVEF以评估早期改善情况。
  • 早期LVEF改善≥10个百分点可作为识别5年死亡风险较低患者的参考指标。
  • 无论患者是否合并冠心病或既往心肌梗死,早期LVEF改善与5年全因死亡的关联均一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In patients with severe aortic stenosis and left ventricular ejection fraction (LVEF) less than 50%, early LVEF improvement after transcatheter aortic valve replacement (TAVR) is associated with improved 1-year mortality; however, its association with long-term clinical outcomes is not known. OBJECTIVE: To examine the association between early LVEF improvement after TAVR and 5-year outcomes. DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed patients enrolled in the Placement of Aortic Transcatheter Valves (PARTNER) 1, 2, and S3 trials and registries between July 2007 and April 2015. High- and intermediate-risk patients with baseline LVEF less than 50% who underwent transfemoral TAVR were included in the current study. Data were analyzed from August 2020 to May 2021. EXPOSURES: Early LVEF improvement, defined as increase of 10 percentage points or more at 30 days and also as a continuous variable (ΔLVEF between baseline and 30 days). MAIN OUTCOMES AND MEASURES: All-cause death at 5 years. RESULTS: Among 659 included patients with LVEF less than 50%, 468 (71.0%) were male, and the mean (SD) age was 82.4 (7.7) years. LVEF improvement within 30 days following transfemoral TAVR occurred in 216 patients (32.8%) (mean [SD] ΔLVEF, 16.4 [5.7%]). Prior myocardial infarction, diabetes, cancer, higher baseline LVEF, larger left ventricular end-diastolic diameter, and larger aortic valve area were independently associated with lower likelihood of LVEF improvement. Patients with vs without early LVEF improvement after TAVR had lower 5-year all-cause death (102 [50.0%; 95% CI, 43.3-57.1] vs 246 [58.4%; 95% CI, 53.6-63.2]; P = .04) and cardiac death (52 [29.5%; 95% CI, 23.2-37.1] vs 135 [38.1%; 95% CI, 33.1-43.6]; P = .05). In multivariable analyses, early improvement in LVEF (modeled as a continuous variable) was associated with lower 5-year all-cause death (adjusted hazard ratio per 5% increase in LVEF, 0.94 [95% CI, 0.88-1.00]; P = .04) and cardiac death (adjusted hazard ratio per 5% increase in LVEF, 0.90 [95% CI, 0.82-0.98]; P = .02) after TAVR. Restricted cubic spline analysis demonstrated a visual inflection point at ΔLVEF of 10% beyond which there was a steep decline in all-cause mortality with increasing degree of LVEF improvement. There were no statistically significant differences in rehospitalization, New York Heart Association functional class, or Kansas City Cardiomyopathy Questionnaire Overall Summary score at 5 years in patients with vs without early LVEF improvement. In subgroup analysis, the association between early LVEF improvement and 5-year all-cause death was consistent regardless of the presence or absence of coronary artery disease or prior myocardial infarction. CONCLUSIONS AND RELEVANCE: In patients with severe aortic stenosis and LVEF less than 50%, 1 in 3 experience LVEF improvement within 1 month after TAVR. Early LVEF improvement is associated with lower 5-year all-cause and cardiac death.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Kolte D, Bhardwaj B, Lu M, et al. Association Between Early Left Ventricular Ejection Fraction Improvement After Transcatheter Aortic Valve Replacement and 5-Year Clinical Outcomes. JAMA Cardiol. 2022. PMID: 35895046. doi:10.1001/jamacardio.2022.2222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。